相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides
Truc T. Tran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
Randall K. Hoover et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
646. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
Cecilia G Carvalhaes et al.
Open Forum Infectious Diseases (2022)
In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium
Cristina Lagatolla et al.
ANTIBIOTICS-BASEL (2022)
Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications
Matteo Bassetti et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2021)
Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital
Kimberly Saddler et al.
PLOS ONE (2021)
Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation
Jullian P. Nguyen et al.
IDCASES (2020)
Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs
Aileen Ahiskali et al.
BMC PHARMACOLOGY & TOXICOLOGY (2020)
Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience
Lauren E. Brownell et al.
DRUGS-REAL WORLD OUTCOMES (2020)
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Nicholas W. Van Hise et al.
DRUGS-REAL WORLD OUTCOMES (2020)
A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
Warren E. Rose et al.
DRUGS-REAL WORLD OUTCOMES (2020)
On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections
Taylor Morrisette et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin
Samira Dahesh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
Mark Redell et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review
Daniel B. Chastain et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
SANRA-a scale for the quality assessment of narrative review articles
Christopher Baethge et al.
RESEARCH INTEGRITY AND PEER REVIEW (2019)
Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections
Lucas T. Schulz et al.
PHARMACOTHERAPY (2018)
Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays
Qun Yan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection
Qun Yan et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci
Qun Yan et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Evaluation of Oritavancin Use at a Community Hospital
Daniel Co et al.
HOSPITAL PHARMACY (2018)
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin
Dino J. Delaportas et al.
PHARMACOTHERAPY (2017)
Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
Michael A Pfaller et al.
Open Forum Infectious Diseases (2017)
Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
Cassie L. Stewart et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci
Jordan R. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Prolonged use of oritavancin for vancomycin-resistantEnterococcus faeciumprosthetic valve endocarditis
Jennifer A. Johnson et al.
Open Forum Infectious Diseases (2015)
Single-Dose Oritavancin Versus 7-10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2015)
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
G. Ralph Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oritavancin: An investigational lipoglycopeptide antibiotic
Lamis R. Karaoui et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2013)
Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro
Adam Belley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
SM Bhavnani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
分享论文
